DE3751092D1 - Herstellung und Immunogenität von Rotavirus-Genen mittels eines Bakulovirus-Expressionssystems. - Google Patents

Herstellung und Immunogenität von Rotavirus-Genen mittels eines Bakulovirus-Expressionssystems.

Info

Publication number
DE3751092D1
DE3751092D1 DE3751092T DE3751092T DE3751092D1 DE 3751092 D1 DE3751092 D1 DE 3751092D1 DE 3751092 T DE3751092 T DE 3751092T DE 3751092 T DE3751092 T DE 3751092T DE 3751092 D1 DE3751092 D1 DE 3751092D1
Authority
DE
Germany
Prior art keywords
immunogenicity
production
expression system
baculovirus expression
rotavirus genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3751092T
Other languages
English (en)
Other versions
DE3751092T2 (de
Inventor
Mary K Estes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of DE3751092D1 publication Critical patent/DE3751092D1/de
Application granted granted Critical
Publication of DE3751092T2 publication Critical patent/DE3751092T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses
DE3751092T 1986-12-30 1987-12-22 Herstellung und Immunogenität von Rotavirus-Genen mittels eines Bakulovirus-Expressionssystems. Expired - Fee Related DE3751092T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/947,773 US5186933A (en) 1986-12-30 1986-12-30 Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system

Publications (2)

Publication Number Publication Date
DE3751092D1 true DE3751092D1 (de) 1995-03-30
DE3751092T2 DE3751092T2 (de) 1995-06-14

Family

ID=25486741

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3751092T Expired - Fee Related DE3751092T2 (de) 1986-12-30 1987-12-22 Herstellung und Immunogenität von Rotavirus-Genen mittels eines Bakulovirus-Expressionssystems.

Country Status (6)

Country Link
US (4) US5186933A (de)
EP (1) EP0273366B1 (de)
JP (1) JPS63273478A (de)
AU (1) AU618521B2 (de)
CA (1) CA1339732C (de)
DE (1) DE3751092T2 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374426A (en) * 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
CA1319101C (en) * 1986-09-03 1993-06-15 Marta Iris Sabara Rotavirus nucleocapsid protein with or without binding peptides as immunologic carriers for macromolecules
AU621065B2 (en) * 1987-08-10 1992-03-05 University Of Melbourne, The Molecular cloning of human rotavirus serotype 4 gene 9 encoding vp7, the major outer capsid neutralisation specific glycoprotein and expression of vp7 and fragments thereof for use in a vaccine
EP0402354A4 (en) * 1987-08-10 1991-03-20 The University Of Melbourne Molecular cloning of human rotavirus serotype 4 gene 9 encoding vp7, the major outer capsid neutralisation specific glycoprotein and expression of vp7 and fragments thereof for use in a vaccine
GB9000143D0 (en) * 1990-01-04 1990-03-07 Natural Environment Res Test kit and method for the diagnosis of bluetongue
US5298244A (en) * 1990-10-25 1994-03-29 University Of Saskatchewan Assembled viral particles and their use in a vaccine to rotaviral disease
PT100090A (pt) * 1991-02-04 1993-07-30 Univ Saskatchewan Metodo de preparacao de uma composicao capz de libertar um agente biologicamente activo para um alvo, e de encapsulacao do referido agente em esferas da proteina vp6
ATE141515T1 (de) * 1991-02-04 1996-09-15 Univ Saskatchewan Arzneistoffabgabe aus vp6-kapseln
US5431899A (en) * 1991-02-04 1995-07-11 University Of Saskatchewan Rotavirus VP6 as a diagnostic and targeting agent
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US6165993A (en) * 1992-03-23 2000-12-26 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
CA2144651A1 (en) * 1992-09-14 1994-03-31 Timothy J. Miller Immortalized cells and uses therefor
CA2179394A1 (en) * 1993-12-23 1995-06-29 Kostas Iatrou Methods of expressing proteins in insect cells and methods of killing insects
US6673355B1 (en) 1995-06-14 2004-01-06 Baylor College Of Medicine Rotavirus enterotoxin NSP4 and methods of using same
CA2224697A1 (en) 1995-06-14 1997-01-03 Peng Tian Rotavirus enterotoxin nsp4 and methods of using same
US6270795B1 (en) * 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
US6582691B1 (en) * 1998-02-12 2003-06-24 Aventis Research & Technologies Gmbh & Co. Expression vector for the production of dead proteins
CA2427809A1 (en) * 2000-11-03 2002-05-10 Baylor College Of Medicine Rotavirus enterotoxin nsp4 and methods of using same
KR20030026654A (ko) * 2001-09-26 2003-04-03 주식회사 씨트리 인간 로타바이러스의 활성을 저해하는 항체의 생산용 항원및 그의 제조방법과 이용
AU2003213167A1 (en) * 2002-02-27 2003-09-09 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Sequence analysis of the tetravalent rotavirus vaccine
AU2004210665A1 (en) * 2003-02-05 2004-08-26 Amphora Discovery Corporation Topical delivery of cosmetic agents
AU2005211385B2 (en) * 2004-02-02 2008-12-11 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
WO2006009901A2 (en) * 2004-06-18 2006-01-26 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
US7638299B2 (en) * 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
MX2007007591A (es) * 2004-12-22 2007-07-25 Ambrx Inc Metodos para expresion y purificacion de hormona de crecimiento humano recombinante.
MX2007007590A (es) 2004-12-22 2007-12-10 Ambrx Inc Composiciones que contienen, metodos que involucran y usos de aminoacidos no naturales y polipeptidos.
ATE542920T1 (de) * 2004-12-22 2012-02-15 Ambrx Inc Modifiziertes menschliches wachstumshormon
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
EP1836298B1 (de) * 2004-12-22 2012-01-18 Ambrx, Inc. Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
CN103030690A (zh) * 2005-06-03 2013-04-10 Ambrx公司 经改良人类干扰素分子和其用途
KR101285904B1 (ko) 2005-08-18 2013-07-15 암브룩스, 인코포레이티드 ｔＲＮＡ 조성물 및 이의 용도
BRPI0504441A (pt) * 2005-10-20 2007-06-26 Fundacao Oswaldo Cruz vetores de expressão plasmidial contendo regiões especìficas para a expressão de proteìnas ou epìtopos recombinantes de rotavìrus e astrovìrus, processo de produção dos insumos para geração de imunobiológicos para diagnóstico
CN101400646A (zh) * 2005-11-08 2009-04-01 Ambrx公司 用于修饰非天然氨基酸和非天然氨基酸多肽的促进剂
US20090018029A1 (en) * 2005-11-16 2009-01-15 Ambrx, Inc. Methods and Compositions Comprising Non-Natural Amino Acids
CN105384807A (zh) * 2005-12-14 2016-03-09 Ambrx公司 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途
SG174781A1 (en) * 2006-09-08 2011-10-28 Ambrx Inc Hybrid suppressor trna for vertebrate cells
AU2007292903B2 (en) 2006-09-08 2012-03-29 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
JP5451390B2 (ja) * 2006-09-08 2014-03-26 アンブルックス，インコーポレイテッド 脊椎動物細胞内におけるサプレッサーｔｒｎａの転写
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
CA2685596A1 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
NZ584825A (en) 2007-11-20 2013-03-28 Ambrx Inc Modified insulin polypeptides and their uses
JP5702150B2 (ja) 2008-02-08 2015-04-15 アンブルックス, インコーポレイテッドAmbrx, Inc. 修飾されているレプチンポリペプチドおよびそれらの使用
JP5680534B2 (ja) 2008-07-23 2015-03-04 イーライ リリー アンド カンパニー 修飾されているウシｇ−ｃｓｆポリペプチドおよびそれらの使用
PL2342223T3 (pl) 2008-09-26 2017-09-29 Ambrx, Inc. Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania
AU2009296267B2 (en) 2008-09-26 2013-10-31 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
CN107674121A (zh) 2009-12-21 2018-02-09 Ambrx 公司 经过修饰的牛促生长素多肽和其用途
CN104017063A (zh) 2009-12-21 2014-09-03 Ambrx公司 经过修饰的猪促生长素多肽和其用途
WO2011136506A2 (ko) * 2010-04-30 2011-11-03 중앙대학교 산학협력단 로타바이러스 나노입자를 이용한 재조합 복합 항원의 제조방법
MX346786B (es) 2010-08-17 2017-03-31 Ambrx Inc Polipeptidos de relaxina modificados y sus usos.
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
MX353786B (es) 2012-02-14 2018-01-29 Merial Inc Vacunas de subunidades de rotavirus, metodos de preparacion y uso de las mismas.
KR102637699B1 (ko) 2014-10-24 2024-02-19 브리스톨-마이어스 스큅 컴퍼니 변형된 fgf-21 폴리펩티드 및 그의 용도
SG11201907209QA (en) 2017-02-08 2019-09-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
CA3152665A1 (en) 2019-08-27 2021-03-04 Tonix Pharma Limited Modified tff2 polypeptides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339735C (en) * 1984-04-27 1998-03-17 Ian Hamilton Holmes. Cloning and sequencing of the major outer capsid gylcoprotein gene of a human rotavirus
AU579242B2 (en) * 1985-05-23 1988-11-17 Comalco Aluminium Limited Bauxite proppant
US4853333A (en) * 1985-07-26 1989-08-01 American Home Products Corporation Production of rotavirus in yeast
EP0251467A3 (de) * 1986-06-20 1988-07-20 Abbott Laboratories Zusammensetzungen und Verfahren zum Gebrauch eines Haupt-Aussen-Kapsid-Proteins (VP7) des Rotavirus SA-11
US4861845A (en) * 1988-03-10 1989-08-29 E. I. Du Pont De Nemours And Company Polymerization of fluoroolefins

Also Published As

Publication number Publication date
EP0273366B1 (de) 1995-02-22
EP0273366A1 (de) 1988-07-06
US5827696A (en) 1998-10-27
US5891676A (en) 1999-04-06
CA1339732C (en) 1998-03-17
DE3751092T2 (de) 1995-06-14
AU8310887A (en) 1988-06-30
US5843733A (en) 1998-12-01
JPS63273478A (ja) 1988-11-10
AU618521B2 (en) 1992-01-02
US5186933A (en) 1993-02-16

Similar Documents

Publication Publication Date Title
DE3751092T2 (de) Herstellung und Immunogenität von Rotavirus-Genen mittels eines Bakulovirus-Expressionssystems.
DE3789399D1 (de) Herstellung von Vakkzinen gegen Hepatitis B-Virus.
DE3785389T2 (de) Herstellung eines kabels.
DE3780933T2 (de) Herstellung von aminoalanen.
DE68919986T2 (de) Herstellung eines Katheters.
DE3650339T2 (de) Herstellung von Urandioxid-Material.
DE3786091D1 (de) Herstellung tomographischer abbildungen.
DE3785132T2 (de) Herstellung optisch aktiver cyclopropancarbonsäuren.
DE3688937T2 (de) Herstellung optisch aktiver aryloxypropanolamine und arylaethanolamine.
DE3789316T2 (de) Herstellung von human-parathyroidhormon.
DE3778134D1 (de) Kontinuierliche herstellung von dialkansulfonylperoxiden.
DE68921340D1 (de) Herstellung von epoxinitraten.
DE3787499D1 (de) Herstellung eines Plasminogenaktivators.
DE68907733D1 (de) Herstellung von duesen.
DE3765326D1 (de) Herstellung eines gummischaumes.
DE343495T1 (de) Herstellung von alkylsilanen.
DE68905638D1 (de) Herstellung von alkansulfonylhaliden und alkansulfonsaeuren.
DE3582180D1 (de) Lebender attenuierter menschlicher rotavirus-impfstoff und herstellung desselben.
DE69007152D1 (de) Herstellung eines Difluorhalogenmethoxybenzols.
DE3777709D1 (de) Verwendung von 3'azido-3'deoxythymidin zur herstellung eines arzneimittels zur behandlung von gardiasis.
DE68906449T2 (de) Herstellung von 2,6-dioxopiperidinderivate.
DE3766873D1 (de) Herstellung von substituierten dichlormethylpyridinen.
DE3880110D1 (de) Herstellung von m-aminophenol.
DE3773219D1 (de) Herstellung von tetrachlorpyridin.
DE3783599D1 (de) Biologische regulierung der dehydratisierung und des verfaulens von wurzeln und herstellung einer impfung dafuer.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee